United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells $3,142,700.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,508,331.70. This represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Up 1.1%

UTHR stock traded up $3.08 during mid-day trading on Monday, reaching $287.35. 397,145 shares of the company traded hands, compared to its average volume of 445,911. The firm's 50 day moving average price is $301.19 and its 200 day moving average price is $324.08. The stock has a market cap of $12.96 billion, a price-to-earnings ratio of 11.47, a P/E/G ratio of 6.22 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $250.60 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.17 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on UTHR shares. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Morgan Stanley upped their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Finally, Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $386.15.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC boosted its stake in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Norges Bank purchased a new position in United Therapeutics in the fourth quarter worth $151,764,000. FMR LLC boosted its position in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new position in United Therapeutics in the 1st quarter valued at $101,354,000. Finally, Nuveen LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at $83,533,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.